As of 2025-09-16, the EV/EBITDA ratio of OncoCyte Corp (OCX) is -6.35. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. OCX's latest enterprise value is 91.52 mil USD. OCX's TTM EBITDA according to its financial statements is -14.41 mil USD. Dividing these 2 quantities gives us the above OCX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.3x - 14.3x | 13.3x |
| Forward P/E multiples | 16.3x - 33.7x | 19.1x |
| Fair Price | (8.19) - (7.19) | (8.16) |
| Upside | -356.1% - -324.6% | -355.1% |
| Date | EV/EBITDA |